BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24319223)

  • 1. How should we treat newly diagnosed multiple myeloma patients?
    Mateos MV; San Miguel JF
    Hematology Am Soc Hematol Educ Program; 2013; 2013():488-95. PubMed ID: 24319223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial treatment of transplant-ineligible patients in multiple myeloma.
    Mateos MV; Leleu X; Palumbo A; San Miguel JF
    Expert Rev Hematol; 2014 Feb; 7(1):67-77. PubMed ID: 24308500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of multiple myeloma in the newly diagnosed patient.
    Mateos MV; San Miguel JF
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):498-507. PubMed ID: 29222298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for patients with newly diagnosed multiple myeloma in 2015.
    Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
    Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical treatment of newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Expert Rev Hematol; 2015 Oct; 8(5):595-611. PubMed ID: 26327587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
    Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
    Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.
    San Miguel JF; Mateos MV
    Leuk Suppl; 2013 May; 2(Suppl 1):S21-7. PubMed ID: 27175257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
    Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
    Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
    Romano A; Santoro M; Conticello C; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):13-20. PubMed ID: 32955184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of patients with relapsed multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R; Palumbo A
    Cancer Treat Rev; 2015 Dec; 41(10):827-35. PubMed ID: 26296679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I manage the toxicities of myeloma drugs.
    Delforge M; Ludwig H
    Blood; 2017 Apr; 129(17):2359-2367. PubMed ID: 28275090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Future Oncol; 2015; 11(11):1643-58. PubMed ID: 25857329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel generation of agents with proven clinical activity in multiple myeloma.
    Mateos MV; Ocio EM; San Miguel JF
    Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
    Guglielmelli T; Palumbo A
    Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with multiple myeloma over 65 yr: more tolerability or better response?
    Tarkun P; Atalay F; Atesoglu EB; Mehtap O; Simsek M; Terzi E; Geduk A; Balli F; Batman A; Baydemir C; Hacihanefioglu A
    Eur J Haematol; 2015 May; 94(5):424-30. PubMed ID: 25220635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.